腫瘤壞死因子抑制劑藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023年全球腫瘤壞死因子（TNF）抑制劑藥物市值為413億美元，預計2024-2032年複合年成長率為2.2%。該市場的成長很大程度上歸因於牛皮癬、類風濕性關節炎和發炎性腸道疾病等自體免疫疾病發生率的增加。隨著對這些疾病的認知和診斷能力的提高，對有效治療方案的需求顯著增加。 TNF 抑制劑因其在控制慢性發炎性疾病症狀方面的功效而聞名，已成為治療方案的關鍵組成部分。

整個腫瘤壞死因子抑制劑藥物產業根據藥物類別、適應症、給藥途徑、配銷通路和地區進行分類。

腫瘤壞死因子抑制劑藥物市場依藥物類別分為聚乙二醇賽妥珠單抗、阿達木單抗、英夫利西單抗、依那西普和戈利木單抗。 2023年，阿達木單抗領域領先市場，估值達242億美元。阿達木單抗是一種專注於腫瘤壞死因子（TNF）的單株抗體，由於其廣泛的療效、值得稱讚的安全性以及在各種自體免疫疾病中的廣泛使用，在TNF 抑制劑藥物領域擁有巨大的市場佔有率。新穎配方和給藥方法的不斷開發增強了其市場地位。

依適應症細分，腫瘤壞死因子抑制劑藥物市場包括化膿性汗腺炎、類風濕性關節炎、乾癬性乾癬性關節炎、乾癬、克隆氏症、僵直性脊椎炎、潰瘍性結腸炎、幼年特發性關節炎等。 2023年，類風濕性關節炎細分市場以42.0%的佔有率引領市場。類風濕性關節炎（RA）是一種主要影響關節的慢性發炎性疾病，導致疼痛、腫脹和潛在的關節損傷，導致大量患者尋求有效的治療。 RA 盛行率的上升，加上認知度和診斷率的提高，刺激了 RA 治療中對 TNF 抑制劑的需求。

2023年，北美引領全球腫瘤壞死因子抑制劑藥物市場，營收達到170億美元，預計到2032年可能達到200億美元。它們處於開發創新TNF 抑制劑的前沿。北美強大的醫療保健系統與既定的監管途徑相結合，確保了新療法的快速進入和接受。患者意識的提高和獲得尖端治療方案的機會鞏固了北美在全球 TNF 抑制劑藥物市場的主導地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 自體免疫疾病盛行率增加
    • 擴大治療適應症
    • 生物技術和藥物開發的進步
  • 產業陷阱與挑戰
    • 治療費用高
    • 副作用和安全問題
• 成長潛力分析
• 監管環境
• 管道分析
• 專利分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 阿達木單抗
  • 品牌化
  • 生物相似藥
• 依那西普
  • 品牌化
  • 生物相似藥
• 英夫利西單抗
  • 品牌化
  • 生物相似藥
• 戈利木單抗
• 聚乙二醇賽妥珠單抗

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

• 主要趨勢
• 類風濕關節炎
• 牛皮癬
• 銀屑病關節炎
• 克隆氏症
• 潰瘍性結腸炎
• 僵直性脊椎炎
• 幼年特發性關節炎
• 化膿性汗腺炎
• 其他適應症

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 皮下注射
• 靜脈注射

第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bio-Thera Solutions, Ltd.
• Janssen Biotech, Inc.
• Merck and Co., Inc.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Group AG
• UCB, Inc.

The Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market was valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from 2024-2032. The market's growth is largely attributed to the increasing incidence of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. As awareness and diagnostic capabilities for these conditions improve, the demand for effective treatment options has risen significantly. TNF inhibitors, known for their efficacy in controlling symptoms of chronic inflammatory diseases, have become a key component in treatment protocols.

The overall tumor necrosis factor inhibitor drugs industry is classified based on the drug class, indication, route of administration, distribution channel, and region.

The tumor necrosis factor inhibitor drugs market is categorized by drug class into certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. In 2023, the adalimumab segment led the market, commanding a valuation of USD 24.2 billion. Adalimumab, a monoclonal antibody with a focus on tumor necrosis factor (TNF), boasts a significant market share in the TNF inhibitor drugs arena, thanks to its broad efficacy, commendable safety profile, and prevalent use across various autoimmune diseases. The continuous development of novel formulations and delivery methods bolsters its market presence.

Segmented by indication, the tumor necrosis factor inhibitor drugs market includes hidradenitis suppurativa, rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, juvenile idiopathic arthritis, and other conditions. In 2023, the rheumatoid arthritis segment led the market with a 42.0% share. Rheumatoid arthritis (RA) is a chronic inflammatory disorder primarily impacting joints, leading to pain, swelling, and potential joint damage, resulting in a significant patient population seeking effective treatment. The rising prevalence of RA, combined with heightened awareness and diagnostic rates, has spurred the demand for TNF inhibitors in RA treatment.

In 2023, North America led the global tumor necrosis factor inhibitor drugs market with revenues reaching USD 17 billion, and projections suggest it could hit USD 20 billion by 2032. The region's leadership is largely due to the presence of top-tier pharmaceutical and biopharmaceutical companies, which are at the forefront of developing innovative TNF inhibitors. North America's strong healthcare system, paired with established regulatory pathways, ensures swift market entry and acceptance of new therapies. Heightened patient awareness and access to cutting-edge treatment options solidify North America's dominant stance in the global TNF inhibitor drugs market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of autoimmune diseases
    • 3.2.1.2 Expansion of therapeutic indications
    • 3.2.1.3 Advancements in biotechnology and drug development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Patent analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Adalimumab
  • 5.2.1 Branded
  • 5.2.2 Biosimilar
• 5.3 Etanercept
  • 5.3.1 Branded
  • 5.3.2 Biosimilar
• 5.4 Infliximab
  • 5.4.1 Branded
  • 5.4.2 Biosimilar
• 5.5 Golimumab
• 5.6 Certolizumab pegol

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Rheumatoid arthritis
• 6.3 Psoriasis
• 6.4 Psoriatic arthritis
• 6.5 Crohn's disease
• 6.6 Ulcerative colitis
• 6.7 Ankylosing spondylitis
• 6.8 Juvenile idiopathic arthritis
• 6.9 Hidradenitis suppurativa
• 6.10 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Subcutaneous injection
• 7.3 Intravenous injection

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
• 10.4 Bio-Thera Solutions, Ltd.
• 10.5 Janssen Biotech, Inc.
• 10.6 Merck and Co., Inc.
• 10.7 Pfizer Inc.
• 10.8 Samsung Bioepis Co., Ltd.
• 10.9 Sandoz Group AG
• 10.10 UCB, Inc.